Compare Biogen Inc (BIIB) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Msci Inc — how do they compare? Biogen Inc trades at $193.38 (market cap $28.34B), while Msci Inc trades at $627.72 (market cap $44.51B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays a 1.34% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MSCI | |
|---|---|---|
Market Cap | $28.34B | $44.51B |
Sector | Health | Financials |
52-Week High | $216.63 | $643.83 |
52-Week Low | $122.68 | $511.84 |
Enterprise Value | $30.62B | $50.68B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
MSCI trades at $620.23, up 2.57% with bullish technical signals and strong earnings beats. The company shows robust fundamentals with 2025 revenue of $3.13B and net income of $1.20B, supported by high margins. Recent news highlights strategic partnerships with UBS and acquisitions to enhance private markets and climate risk capabilities, reinforcing growth prospects amid positive analyst sentiment.
Outlook remains positive with a consensus price target of $718.14, though elevated P/E of 35.42 and high debt levels pose valuation and financial risks. Earnings growth and strategic expansions are key catalysts, but investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
